- August 2, 2010 at 7:29 pm
The c-kit thing was odd, but it speaks to the future of cancer treatment. Glevec was tested in leukemia and the mechanism for action was to block c-kit. Someone in melanoma realized that a lot of acral and mucosal melanomas have that mutation too, so it might work there. And it does.
I think increasingly, drugs will be developed with a specific mechanism of action, and will be used across many tumor types so long as they involve that mechanism.
There is some early evidence of a biomarker for IL-2 response. A small paper was published a year ago that people with VEGF levels above 130 pg/ml did not respond to IL-2. Might be worth having his VEGF levels tested (pronouced vef – F) before deciding on IL-2. Howard Kaufman, from Rush in Chicago, did that study. He does a lot of IL-2.